Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN – Get Free Report) was the target of a significant decline in short interest in the month of June. As of June 15th, there was short interest totaling 1,344 shares, a decline of 73.0% from the May 31st total of 4,982 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily volume of 4,313 shares, the short-interest ratio is currently 0.3 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Wednesday, April 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.
Get Our Latest Research Report on ADXN
Addex Therapeutics Stock Performance
Addex Therapeutics (NASDAQ:ADXN – Get Free Report) last announced its earnings results on Thursday, June 25th. The company reported ($1.50) earnings per share (EPS) for the quarter. The company had revenue of $0.01 million for the quarter.
Addex Therapeutics Company Profile
Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.
The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.
Featured Stories
- Five stocks we like better than Addex Therapeutics
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
